PURPOSE: Drug development is often hindered by a drug's low dissolution rate. We present a method to increase dissolution rate of a drug powder by producing crystalline nanoparticles that are dispersed in carrier microparticles. METHODS: Indomethacin crystals of a few hundred nanometers are prepared by media milling using poloxamer 188 as a stabilizer. Nanoparticles are embedded into microparticles with a mannitol matrix and an L-leucine coating layer using an aerosol flow reactor method. RESULTS: Microparticles stabilize the primary nanoparticles in an intact crystalline form and release them when re-dispersed in aqueous medium. Secondary microparticle structure dissolves rapidly, resulting in a fast release and dissolution of indomethacin. In this manner, it is possible to change the surface layer of the particles from the one needed for nanoparticle production to one more suitable for process formulation of pharmaceuticals for, e.g., tablet or pulmonary products. CONCLUSIONS: Particle assemblies where nano-sized crystalline drug domains are embedded in solid microparticles are presented. The present work is a promising approach towards a "nanos-in-micros" concept as a tool for pharmaceutical nanoparticle processing.
PURPOSE: Drug development is often hindered by a drug's low dissolution rate. We present a method to increase dissolution rate of a drug powder by producing crystalline nanoparticles that are dispersed in carrier microparticles. METHODS:Indomethacin crystals of a few hundred nanometers are prepared by media milling using poloxamer 188 as a stabilizer. Nanoparticles are embedded into microparticles with a mannitol matrix and an L-leucine coating layer using an aerosol flow reactor method. RESULTS: Microparticles stabilize the primary nanoparticles in an intact crystalline form and release them when re-dispersed in aqueous medium. Secondary microparticle structure dissolves rapidly, resulting in a fast release and dissolution of indomethacin. In this manner, it is possible to change the surface layer of the particles from the one needed for nanoparticle production to one more suitable for process formulation of pharmaceuticals for, e.g., tablet or pulmonary products. CONCLUSIONS: Particle assemblies where nano-sized crystalline drug domains are embedded in solid microparticles are presented. The present work is a promising approach towards a "nanos-in-micros" concept as a tool for pharmaceutical nanoparticle processing.
Authors: Peng Liu; Xinyu Rong; Johanna Laru; Bert van Veen; Juha Kiesvaara; Jouni Hirvonen; Timo Laaksonen; Leena Peltonen Journal: Int J Pharm Date: 2011-03-31 Impact factor: 5.875
Authors: Janne Raula; Frank Thielmann; Jarno Kansikas; Sami Hietala; Minna Annala; Jukka Seppälä; Anna Lähde; Esko I Kauppinen Journal: Pharm Res Date: 2008-06-27 Impact factor: 4.200
Authors: Peng Liu; Odile De Wulf; Johanna Laru; Teemu Heikkilä; Bert van Veen; Juha Kiesvaara; Jouni Hirvonen; Leena Peltonen; Timo Laaksonen Journal: AAPS PharmSciTech Date: 2013-04-25 Impact factor: 3.246